ArticleBioMed research international2026
Illuminating the Co-Phosphoregulatory Network of the Dark Kinase STK10 by Omics Approaches.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serine/threonine-protein kinase 10 (STK10), an ERM protein kinase, functions as a membrane-cytoskeleton linker and regulates lymphocyte cortical rigidity, cell shape, adhesion, and migration. Despite its emerging relevance in immune regulation and cancer, the phosphoregulatory mechanisms governing STK10 remain poorly understood. To address this, we systematically assembled and mapped the global phosphoproteomic datasets on the dark STK10 phosphosites. From 453 quantitative differential profiles representing STK10 Class 1 phosphosites, 12 predominant sites were identified based on frequency. Of these, four phosphosites (T185, S191, S514, and T952) were conserved with the homologous kinase SLK, indicating evolutionary conservation. Notably, S450, S455, T14, S448, and S454 were predicted as potential autophosphorylation sites, suggesting intrinsic regulatory control. Predictions indicated that PAK2 and MAP3K2 may act as both upstream kinases and downstream substrates of STK10, with their phosphosites (MAP3K2_S153 and PAK2_S141) consistently co-regulated, suggesting a common regulatory axis. These findings stacked the phosphorylation landscape of STK10, extending regulatory insights beyond its kinase domain. This phosphoproteomics data-driven study establishes a framework for prioritizing functional validation and structural investigations to define the physiological and pathological significance of dark phosphosites in STK10 in immunity and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.